

# Evangelos Xylinas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6912579/publications.pdf>

Version: 2024-02-01

161  
papers

5,884  
citations

100601

38  
h-index

104191

69  
g-index

186  
all docs

186  
docs citations

186  
times ranked

5640  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. <i>European Urology Focus</i> , 2022, 8, 491-497.	1.6	13
2	Restaging transurethral resection in ta high-grade nonmuscle invasive bladder cancer: a systematic review. <i>Current Opinion in Urology</i> , 2022, 32, 54-60.	0.9	3
3	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 227-236.	0.9	3
4	Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art. <i>Current Oncology</i> , 2022, 29, 687-697.	0.9	9
5	Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. <i>World Journal of Urology</i> , 2022, 40, 1489-1496.	1.2	3
6	Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 535-535.	0.8	5
7	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 273.e11-273.e20.	0.8	8
8	Lymph Node Dissection During Radical Nephro-Ureterectomy for Upper Tract Urothelial Carcinoma: A Review. <i>Frontiers in Surgery</i> , 2022, 9, 852969.	0.6	6
9	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urologyâ€”Young Academic Urologists: Urothelial Carcinoma Working Group. <i>European Urology Focus</i> , 2022, 8, 1635-1642.	1.6	7
10	Systematic Review and Meta-Analysis on the Role of Perioperative Blood Transfusion in Patients Undergoing Radical Cystectomy for Urothelial Carcinoma. <i>Bladder Cancer</i> , 2022, 8, 315-327.	0.2	1
11	Nomogram Predicting Bladder Cancerâ€”specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium. <i>European Urology Focus</i> , 2021, 7, 1347-1354.	1.6	21
12	Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 580-593.	2.6	19
13	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. <i>World Journal of Urology</i> , 2021, 39, 443-451.	1.2	13
14	Perioperative chemotherapy for upper tract urothelial carcinoma: show me the evidence. <i>Current Opinion in Urology</i> , 2021, 31, 66-67.	0.9	9
15	Frailty impact on postoperative complications and early mortality rates in patients undergoing radical cystectomy for bladder cancer: a systematic review. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 9-23.	0.7	22
16	Immune checkpoint inhibition in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1357-1367.	1.2	27
17	Systematic review and meta-analysis on bipolar versus monopolar transurethral resection of bladder tumors. <i>Translational Andrology and Urology</i> , 2021, 10, 37-48.	0.6	5
18	Assessment of the oncological outcomes of three different bacillus Calmetteâ€”GuÃ©rin strains in patients with high-grade T1 non-muscle-invasive bladder cancer. <i>Arab Journal of Urology Arab Association of Urology</i> , 2021, 19, 78-85.	0.7	6

#	ARTICLE	IF	CITATIONS
19	Immunotherapy in genitourinary cancers: achievements and perspectives. <i>World Journal of Urology</i> , 2021, 39, 1317-1317.	1.2	0
20	Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer. <i>Medicina (Lithuania)</i> , 2021, 57, 769.	0.8	22
21	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	1.2	4
22	Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 885-893.	0.2	11
23	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. <i>European Urology</i> , 2021, 80, 507-515.	0.9	27
24	Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review. <i>European Urology Focus</i> , 2021, 7, 1075-1083.	1.6	5
25	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology Oncology</i> , 2021, 4, 927-942.	2.6	40
26	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. <i>Minerva Urology and Nephrology</i> , 2021, , .	1.3	4
27	The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	3
28	Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. <i>European Urology Focus</i> , 2020, 6, 1226-1232.	1.6	18
29	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. <i>European Urology</i> , 2020, 77, 1-2.	0.9	3
30	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. <i>European Urology Oncology</i> , 2020, 3, 94-101.	2.6	41
31	Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 73-79.	2.6	29
32	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	0.8	29
33	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132
34	Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit. <i>Journal of Clinical Medicine</i> , 2020, 9, 3306.	1.0	4
35	The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review. <i>Progres En Urologie</i> , 2020, 30, 322-331.	0.3	7
36	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. <i>Surgical Oncology</i> , 2020, 34, 312-317.	0.8	7

#	ARTICLE	IF	CITATIONS
37	PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment. <i>World Journal of Urology</i> , 2020, 39, 4055-4065.	1.2	11
38	Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes. <i>World Journal of Urology</i> , 2020, 39, 2545-2552.	1.2	16
39	Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer â€œexamining the utility of classifying Ta bladder cancer based on size. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 851.e19-851.e25.	0.8	6
40	Consensus Definition and Prediction of Complexity in Transurethral Resection or Bladder Endoscopic Dissection of Bladder Tumours. <i>Cancers</i> , 2020, 12, 3063.	1.7	7
41	Comparison of the Comprehensive Complication Index and Clavien-Dindo systems in predicting perioperative outcomes following radical nephroureterectomy. <i>Translational Andrology and Urology</i> , 2020, 9, 1780-1785.	0.6	8
42	Incidence and preoperative predictors for major complications following radical nephroureterectomy. <i>Translational Andrology and Urology</i> , 2020, 9, 1786-1793.	0.6	10
43	Postoperative Chemotherapy Bladder Instillation After Radical Nephroureterectomy: Results of a European Survey from the Young Academic Urologist Urothelial Cancer Group. <i>European Urology Open Science</i> , 2020, 22, 45-50.	0.2	6
44	The Impact of Restaging Transurethral Resection of Bladder Tumor on Survival Parameters in T1 Nonmuscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis. <i>Journal of Endourology</i> , 2020, 34, 795-804.	1.1	13
45	Re: Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 113-114.	0.9	14
46	Tumores primarios de la uretra en el varÃ³n. <i>EMC - UrologÃa</i> , 2020, 52, 1-5.	0.0	0
47	Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1962.	1.0	9
48	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	0.8	15
49	The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical) Tj ETQq1 1 0.784314 rgBT /Overlock 10 <i>Urology</i> , 2020, 18, 67-71.	0.7	11
50	Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 165-172.	1.2	7
51	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1192.	1.0	13
52	Lymphadenectomy for Upper Tract Urothelial Carcinoma: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2019, 8, 1190.	1.0	17
53	Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 76-85.	2.0	9
54	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. <i>Nature Communications</i> , 2019, 10, 2977.	5.8	140

#	ARTICLE	IF	CITATIONS
55	Prediction tools in non-muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 39-45.	0.6	14
56	Differences in trends in the use of robotâ€‘assisted and open radical cystectomy and changes over time in periâ€‘operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. <i>BJU International</i> , 2019, 124, 656-664.	1.3	53
57	The need to improve TURB: a diagnostic and therapeutic fundamental first step in the diseaseâ€™s management. <i>Translational Andrology and Urology</i> , 2019, 8, 2-4.	0.6	4
58	The present and future of non-muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 1-1.	0.6	1
59	Re: Impact of Adjuvant Chemotherapy in Patients with Adverse Features and Variant Histology at Radical Cystectomy for Muscle-invasive Carcinoma of the Bladder: Does Histologic Subtype Matter?. <i>European Urology</i> , 2019, 76, 256-257.	0.9	0
60	Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. <i>BJU International</i> , 2019, 124, 738-745.	1.3	32
61	Active surveillance for non-muscle invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, 54-60.	0.6	14
62	Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721882367.	0.9	10
63	EAUâ€™ESMO consensus statements on the management of advanced and variant bladder cancerâ€™an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019, 30, 1697-1727.	0.6	96
64	Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1600-1610.	2.1	24
65	Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 179.e1-179.e7.	0.8	8
66	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Nonâ€™muscle-invasive Bladder Cancer: Results of a European Survey. <i>European Urology Focus</i> , 2019, 5, 681-688.	1.6	48
67	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. <i>European Urology Focus</i> , 2019, 5, 242-249.	1.6	11
68	PD-L1/PD-1 expression as a predictor of response to BCG in patients with high-risk nonâ€™muscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4550-4550.	0.8	3
69	Conditional analyses of recurrence and progression in patients with TaG1 nonâ€™muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e19-238.e27.	0.8	3
70	Prevention of IVR: a need for investigation. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 295-296.	0.6	0
71	Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. <i>World Journal of Urology</i> , 2018, 36, 1621-1627.	1.2	29
72	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Nodeâ€™Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Scoreâ€™Weighted Competing Risks Analysis. <i>European Urology Focus</i> , 2018, 4, 252-259.	1.6	18

#	ARTICLE	IF	CITATIONS
73	Impact of body mass index on the oncological outcomes of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2018, 36, 65-71.	1.2	14
74	Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 8.e17-8.e24.	0.8	36
75	Immunotherapy for metastatic urothelial carcinoma. <i>Current Opinion in Urology</i> , 2018, 28, 1-7.	0.9	6
76	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urologyâ€“Young Academic Urologists and theÂUpper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2018, 121, 252-259.	1.3	61
77	Impact of age on outcomes of patients with nonâ€“muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 89.e1-89.e5.	0.8	6
78	Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience. <i>Frontiers in Surgery</i> , 2018, 5, 58.	0.6	16
79	Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. <i>World Journal of Urology</i> , 2018, 36, 1775-1781.	1.2	15
80	Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. <i>World Journal of Urology</i> , 2018, 36, 1727-1740.	1.2	75
81	Impact of body mass index on the oncological outcomes of patients treated with radical cystectomy for muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2017, 35, 229-235.	1.2	25
82	Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. <i>World Journal of Urology</i> , 2017, 35, 337-353.	1.2	74
83	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. <i>World Journal of Urology</i> , 2017, 35, 121-130.	1.2	37
84	External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 33.e21-33.e26.	0.8	10
85	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. <i>World Journal of Urology</i> , 2017, 35, 1401-1407.	1.2	29
86	Re: Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2017, 72, 473-474.	0.9	1
87	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 548-555.e3.	0.9	37
88	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 198, 1253-1262.	0.2	58
89	The contemporary role and impact of urine-based biomarkers in bladder cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 1031-1042.	0.6	29
90	Prognostic value of PD-1 and PD-L1 expression in patients with high-grade urothelial carcinoma of the upper urinary tract.. <i>Journal of Clinical Oncology</i> , 2017, 35, 358-358.	0.8	0



#	ARTICLE	IF	CITATIONS
91	Association of muscle mass with pathologic response and toxicity in localized bladder cancer patients treated by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC).. Journal of Clinical Oncology, 2017, 35, e16022-e16022.	0.8	0
92	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. Bladder Cancer, 2016, 2, 91-99.	0.2	8
93	An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. Biomolecules, 2016, 6, 37.	1.8	44
94	Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. BJU International, 2016, 118, 243-249.	1.3	14
95	Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 483.e17-483.e24.	0.8	54
96	Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making. BJU International, 2016, 117, 272-279.	1.3	29
97	Angiotensin System Inhibitors in Renal Cell Carcinoma Letter. Clinical Cancer Research, 2016, 22, 524-524.	3.2	2
98	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology, 2016, 34, 1155-1161.	1.2	4
99	Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy. European Urology Focus, 2015, 1, 75-81.	1.6	6
100	ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. Journal of Urology, 2015, 194, 1456-1462.	0.2	25
101	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2015, 67, 241-249.	0.9	235
102	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. European Urology, 2015, 67, 803-812.	0.9	78
103	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. European Urology, 2015, 68, 238-253.	0.9	211
104	Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1873-1881.	1.1	21
105	Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and penta-fecta. World Journal of Urology, 2015, 33, 1945-1950.	1.2	28
106	Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. European Urology, 2015, 67, 74-82.	0.9	190
107	Prognostics Factors, Molecular Markers, and Predictive Tools in Upper Tract Urothelial Carcinoma. , 2015, , 91-117.		0
108	Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biology and Therapy, 2014, 15, 1239-1247.	1.5	30

#	ARTICLE	IF	CITATIONS
109	Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. <i>British Journal of Cancer</i> , 2014, 111, 213-219.	2.9	24
110	Impact of perioperative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>BJU International</i> , 2014, 113, 393-398.	1.3	54
111	Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. <i>BJU International</i> , 2014, 114, 56-61.	1.3	41
112	Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1693-1699.	0.5	16
113	Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 49.e7-49.e14.	0.8	38
114	Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. <i>European Journal of Surgical Oncology</i> , 2014, 40, 113-120.	0.5	29
115	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 433-440.	0.8	31
116	Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 625-630.	0.8	25
117	Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. <i>European Urology</i> , 2014, 66, 913-919.	0.9	103
118	Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. <i>European Urology</i> , 2014, 65, 650-658.	0.9	134
119	Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 230-242.	0.8	33
120	Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature. <i>European Urology</i> , 2014, 65, 742-754.	0.9	159
121	Urine markers for detection and surveillance of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 222-229.	0.8	91
122	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 66, 379-385.	0.9	27
123	Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. <i>European Urology</i> , 2014, 66, 439-446.	0.9	24
124	Nephron-Sparing Surgery for Renal Tumors Measuring More Than 7 cm: Morbidity, and Functional and Oncological Outcomes. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e19-e27.	0.9	31
125	Re: Impact of Smoking Status on Bladder Tumor Recurrence after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2014, 191, 557-559.	0.2	0
126	Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 191, 1238-1243.	0.2	26



#	ARTICLE	IF	CITATIONS
127	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. <i>European Urology</i> , 2014, 66, 361-370.	0.9	125
128	Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 47.e1-47.e8.	0.8	8
129	Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. <i>European Journal of Surgical Oncology</i> , 2014, 40, 121-127.	0.5	132
130	Prospective External Validation of a Bladder Cancer Detection Model. <i>Journal of Urology</i> , 2014, 192, 1343-1348.	0.2	35
131	Predictors of Cancer-specific Mortality After Disease Recurrence in Patients with Squamous Cell Carcinoma of the Penis. <i>European Urology</i> , 2014, 66, 811-814.	0.9	12
132	Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 191, 830-841.	0.2	19
133	Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 65, 210-217.	0.9	201
134	Evaluation of combined oncologic and functional outcomes after robotic-assisted laparoscopic extraperitoneal radical prostatectomy: Trifecta rate of achieving continence, potency and cancer control. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 99-103.	0.8	36
135	Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. <i>Journal of Urology</i> , 2013, 189, 468-473.	0.2	40
136	Segmental ureterectomy for upper tract urothelial carcinoma: Two procedures with different indications. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1841-1843.	0.8	3
137	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2013, 31, 5-11.	1.2	39
138	Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2013, 31, 31-36.	1.2	25
139	Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. <i>World Journal of Urology</i> , 2013, 31, 61-68.	1.2	72
140	Robotic-assisted Radical Cystectomy With Extracorporeal Urinary Diversion for Urothelial Carcinoma of the Bladder: Analysis of Complications and Oncologic Outcomes in 175 Patients With a Median Follow-up of 3 Years. <i>Urology</i> , 2013, 82, 1323-1329.	0.5	38
141	Re: Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial. <i>European Urology</i> , 2013, 64, 683-684.	0.9	1
142	Re: Effect of Abiraterone Acetate and Prednisone Compared with Placebo and Prednisone on Pain Control and Skeletal-related Events in Patients with Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis of Data from the COU-AA-301 Randomised Trial. <i>European Urology</i> , 2013, 63, 1132-1133.	0.9	3
143	Robot-assisted extraperitoneal laparoscopic radical prostatectomy: A review of the current literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 288-293.	0.8	11
144	Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. <i>Journal of Urology</i> , 2013, 189, 1214-1221.	0.2	291

#	ARTICLE	IF	CITATIONS
145	Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Cancer</i> , 2013, 49, 1889-1897.	1.3	154
146	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. <i>European Urology</i> , 2013, 64, 456-464.	0.9	101
147	Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1027-1034.	0.7	25
148	Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. <i>British Journal of Cancer</i> , 2013, 109, 1460-1466.	2.9	192
149	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroureterectomy. <i>BJU International</i> , 2013, 112, 453-461.	1.3	128
150	Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. <i>British Journal of Cancer</i> , 2012, 107, 1826-1832.	2.9	34
151	Laparoscopic Partial Nephrectomy: Is It Worth Still Performing the Retroperitoneal Route?. <i>Advances in Urology</i> , 2012, 2012, 1-5.	0.6	13
152	Uptake of Laparoscopic Radical Nephroureterectomy in France: A 2003-2011 National Practice Report. <i>European Urology</i> , 2012, 62, 940-942.	0.9	2
153	Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2012, 188, 2120-2128.	0.2	45
154	Multifocal Carcinoma In Situ of the Upper Tract Is Associated With High Risk of Bladder Cancer Recurrence. <i>European Urology</i> , 2012, 61, 1069-1070.	0.9	94
155	The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. <i>BJU International</i> , 2012, 110, 43-49.	1.3	53
156	Tumeurs urothéliales, incontinence, organes génitaux externes et transplantation rénale. <i>Progrès En Urologie - FMC</i> , 2011, 21, F32-F35.	0.2	0
157	Ureteral and Multifocal Tumours Have Worse Prognosis than Renal Pelvic Tumours in Urothelial Carcinoma of the Upper Urinary Tract Treated by Nephroureterectomy. <i>European Urology</i> , 2011, 60, 1258-1265.	0.9	147
158	Oncologic Outcomes and Survival in pT0 Tumors After Radical Cystectomy in Patients Without Neoadjuvant Chemotherapy: Results from a Large Multicentre Collaborative Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 3833-3838.	0.7	11
159	Intrafascial Nerve-Sparing Radical Prostatectomy with a Laparoscopic Robot-Assisted Extraperitoneal Approach: Early Oncological and Functional Results. <i>Journal of Endourology</i> , 2010, 24, 577-582.	1.1	24
160	Is Robot Assistance Affecting Operating Room Time Compared with Pure Retroperitoneal Laparoscopic Radical Prostatectomy?. <i>Journal of Endourology</i> , 2009, 23, 939-943.	1.1	24
161	HBP, transplantation rénale, vessie et tumeur urothéliale, OGE, neuro-urologie, incontinence de l'homme et de la femme. <i>Progrès En Urologie - FMC</i> , 2008, 18, F33-F37.	0.2	0